Zulresso and the Social Determinants of Health Dynamics of America
Zulresso (brexanolone) was recently approved as the first drug to treat post-partum depression (PPD). It is a medication, and naturally produced steroid that affects...
TriNetX Raises over $100 Million and Showing Up in More Discussions
TriNetX just recently raised another $40 million. The Cambridge, MA-based venture’s newest investors include Merck Global Health Innovation Fund, Mitsui & Co., Ltd., ITOCHU...
The ADAPTABLE Trial: RWD in Action by Using Electronic Health Records & PROs
Known as the Aspirin Study—A Patient-Centered Trial, it showcases use of Real-World Data (RWD) in clinical research. A demonstration project of PCORnet (The National...
The Race to Commercialize a NASH Treatment Requires Money, Execution, and Results
France-based biotech venture Genfit S.A. (OTCPK: GNFTF) recently filed a preliminary prospectus for an initial public offering (IPO) of 5 million American Depository Shares...
ORIEN: Drug Discovery and Development Collaboration
The pursuit of a cancer cure represents a truly collaborative effort requiring both altruistic cooperation and the profit motive of self-interest and entrepreneurial ingenuity. ...
UCSF Team Building Next Generation Blockchain-based Clinical Trial Management System
TrialSite News recently interviewed Daniel R. Wong of Bakar Computational Health Sciences Facility, University of California San Francisco. Mr. Wong, along with Sanchita Bhattacharya...
CHOP 20X Return in 6 years with Roche Acquisition of Spark Therapeutics
Swiss Roche Holding AG recently announced its intension to acquire U.S. biotechnology company Spark Therapeutics Inc. (Spark) as recently reported by NASDAQ. Priced at...
Research, Healthcare and Transparency: Is Information Valuable for the Patient?
TrialSite News recently wrote about the promise and perils of stem cell practices—with a keen eye on unethical and even unlawful medical practices called...
Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?
Recently, a TrialSite News reader—a Hidradenitis Suppurativa (HS) patient—brought a website to our attention. Apparently, this individual, who has been struggling with HS, was...
Price Watch: Does Sanofi & Regeneron Praluent Price Cut a Harbinger of Things to...
Heart disease is the number one killer in America. A few factors contribute to this killer and high cholesterol is a major...
- Advertisement -